

Fasiha Kanwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/820699/publications.pdf>

Version: 2024-02-01

138
papers

8,297
citations

61857

43
h-index

49773

87
g-index

139
all docs

139
docs citations

139
times ranked

9870
citing authors

#	ARTICLE	IF	CITATIONS
1	Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999â€“2018. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 223-225.e3.	2.4	5
2	Risk factors for HCC in contemporary cohorts of patients with cirrhosis. <i>Hepatology</i> , 2023, 77, 997-1005.	3.6	36
3	Long-term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States. <i>Liver Transplantation</i> , 2023, 29, 15-25.	1.3	2
4	Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 9-18.	2.4	58
5	Practical Consideration for Drug Monitoring of Tacrolimus in Liver Transplantation Recipients with SARSâ€“CoVâ€“2 Infection. <i>Liver Transplantation</i> , 2022, 28, 127-130.	1.3	1
6	Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. <i>Journal of Hepatology</i> , 2022, 76, 294-301.	1.8	20
7	Clinical Factors Associated With Lack of Serological Response to SARSâ€“CoVâ€“2 Messenger RNA Vaccine in Liver Transplantation Recipients. <i>Liver Transplantation</i> , 2022, 28, 123-126.	1.3	25
8	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 75, 1289-1299.	3.6	26
9	Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 75, 1420-1428.	3.6	65
10	Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 76, 251-274.	3.6	18
11	AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis. <i>Hepatology</i> , 2022, 76, 819-853.	3.6	56
12	Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. <i>Journal of Hepatology</i> , 2022, 77, 55-62.	1.8	19
13	Significant improvements, but consistent disparities in survival for African Americans after liver transplantation. <i>Clinical Transplantation</i> , 2022, , e14646.	0.8	1
14	Comparable survival for hepatitis C-related hepatocellular carcinoma after liver transplantation irrespective of viremic status. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	0
15	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	0
16	Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet. <i>Hepatology</i> , 2022, 76, 546-548.	3.6	4
17	Reply. <i>Hepatology</i> , 2022, 76, E50-E50.	3.6	0
18	Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2022, 12, 5695.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma. <i>Transplantation Direct</i> , 2022, 8, e1313.	0.8	10
20	Oral Health and the Altered Colonic Mucosa-Associated Gut Microbiota. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2981-2991.	1.1	10
21	Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1443-1450.e6.	2.4	13
22	Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2439-2451.	1.1	23
23	Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. <i>Digestive Diseases and Sciences</i> , 2021, 66, 912-916.	1.1	19
24	Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 61-71.e15.	2.4	159
25	Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure". <i>Journal of Hepatology</i> , 2021, 74, 477.	1.8	0
26	Unconscious Bias in Peer Review. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 419-420.	2.4	13
27	Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Clinical Liver Disease</i> , 2021, 17, 308-308.	1.0	0
28	On the Proposed Definition of Metabolic-Associated Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 865-870.	2.4	33
29	Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 701-711.	1.8	1
30	Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 422-424.	3.7	11
31	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	0
32	Presentation of the AGA William Beaumont Prize in Gastroenterology to David Y. Graham, MD. <i>Gastroenterology</i> , 2021, 161, 333-335.	0.6	0
33	Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021, 44, 2162-2172.	4.3	30
34	Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 949.	2.6	35
35	Spatial Characteristics of Colonic Mucosa-Associated Gut Microbiota in Humans. <i>Microbial Ecology</i> , 2021, , 1.	1.4	10
36	NAFLD and HCC: Time to Bridge the Gap. <i>Hepatology</i> , 2021, 74, 2336-2338.	3.6	3

#	ARTICLE	IF	CITATIONS
37	Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021, 29, 1401-1412.	1.5	7
38	Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021, 161, 1030-1042.e8.	0.6	58
39	Elevated serum sodium in recipients of liver transplantation has a substantial impact on outcomes. <i>Transplant International</i> , 2021, 34, 1971-1983.	0.8	2
40	Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA. <i>Hepatology</i> , 2021, 74, 3316-3329.	3.6	75
41	Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154822.	1.5	25
42	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 161, 1657-1669.	0.6	229
43	Marginal Allografts in Liver Transplantation Have a Limited Impact on Length of Stay. <i>Clinical Transplantation</i> , 2021, , e14544.	0.8	1
44	Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. <i>Hepatology</i> , 2020, 71, 44-55.	3.6	188
45	Integrated Model for Patient-Centered Advanced Liver Disease Care. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1015-1024.	2.4	19
46	Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 808-819.	3.6	170
47	Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. <i>Antiviral Research</i> , 2020, 174, 104698.	1.9	10
48	Renal Trajectory Patterns Are Associated With Postdischarge Mortality in Patients With Cirrhosis and Acute Kidney Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1858-1866.e6.	2.4	11
49	Covering the Year in CGH: 2019. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3-10.	2.4	3
50	The Influence of Gut and Tumor Microbiome on Pancreatic Cancer Outcomes. <i>Gastroenterology</i> , 2020, 159, 1184-1185.	0.6	2
51	Trends in Outcomes for Marginal Allografts in Liver Transplant. <i>JAMA Surgery</i> , 2020, 155, 926.	2.2	48
52	Reply to: "Model for end-stage liver disease-sodium in acute-on-chronic liver failure". <i>Journal of Hepatology</i> , 2020, 73, 1579-1580.	1.8	0
53	Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2020, 73, 1425-1433.	1.8	81
54	Aggressive utilization of liver allografts: Improved outcomes over time. <i>Clinical Transplantation</i> , 2020, 34, e13860.	0.8	1

#	ARTICLE	IF	CITATIONS
55	A learning curve in using orphan liver allografts for transplantation. <i>Clinical Transplantation</i> , 2020, 34, e13821.	0.8	0
56	Retrospective analysis of long-term outcome 10 years after liver transplantation for Wilson disease: experience over three decades. <i>Transplant International</i> , 2020, 33, 925-935.	0.8	3
57	Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. <i>JAMA Network Open</i> , 2020, 3, e2021173.	2.8	15
58	Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. <i>JAMA Network Open</i> , 2020, 3, e2023780.	2.8	45
59	Risk Factors for Cirrhosis in Contemporary Hepatology Practices—Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. <i>Gastroenterology</i> , 2020, 159, 376-377.	0.6	32
60	Early Impact of COVID-19 on Solid Organ Transplantation in the United States. <i>Transplantation</i> , 2020, 104, 2221-2224.	0.5	68
61	Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2020, 12, 628-640.	0.8	2
62	The HCV Treatment Cascade: Race Is a Factor to Consider. <i>Journal of General Internal Medicine</i> , 2019, 34, 1949-1951.	1.3	5
63	Reply to: "Prevalence and short-term mortality in a national US cohort with acute-on-chronic liver failure". <i>Journal of Hepatology</i> , 2019, 71, 638-639.	1.8	1
64	Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. <i>BMJ Open</i> , 2019, 9, e026726.	0.8	34
65	Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1470-1477.	1.1	3
66	AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. <i>Gastroenterology</i> , 2019, 156, 2149-2157.	0.6	90
67	Reply to: "Mortality of acute-on-chronic liver failure: What is the role of obesity?". <i>Journal of Hepatology</i> , 2019, 70, 1301-1302.	1.8	0
68	Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon. <i>Nutrients</i> , 2019, 11, 613.	1.7	48
69	Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 530-532.	0.2	27
70	Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. <i>Journal of Hepatology</i> , 2019, 70, 639-647.	1.8	101
71	Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2019, 69, 1787-1797.	3.6	92
72	Nutrition in Alcoholic Liver Disease. <i>Clinics in Liver Disease</i> , 2019, 23, 99-114.	1.0	18

#	ARTICLE	IF	CITATIONS
73	Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. <i>Journal of Viral Hepatitis</i> , 2019, 26, 596-602.	1.0	67
74	Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 739-747.e8.	2.4	24
75	Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 98-106.	0.2	36
76	Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1677-1678.	2.4	63
77	Hepatology in a changing health care landscape: A call for health services research. <i>Hepatology</i> , 2018, 68, 1154-1162.	3.6	0
78	Patient-reported outcomes in cirrhosis: A scoping review of the literature. <i>Hepatology</i> , 2018, 67, 2375-2383.	3.6	62
79	Cost-effectiveness and Decision Analysis in Clinical Gastroenterology and Hepatology: From Evidence to Informed Decision Making. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 459-461.	2.4	3
80	Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. <i>BMC Medical Research Methodology</i> , 2018, 18, 1.	1.4	390
81	Houston Consensus Conference on Testing for <i>Helicobacter pylori</i> Infection in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 992-1002.e6.	2.4	189
82	Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 115-122.e10.	2.4	21
83	A Randomized Trial of Off-Site Collaborative Care for Depression in Chronic Hepatitis C Virus. <i>Health Services Research</i> , 2018, 53, 2547-2566.	1.0	8
84	Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 252-259.	2.4	47
85	Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. <i>Hepatology</i> , 2018, 67, 2085-2095.	3.6	50
86	Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 1828-1837.e2.	0.6	490
87	Implementation of a Population-Based Cirrhosis Identification and Management System. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1182-1186.e2.	2.4	11
88	Increasing Health Care Burden of Chronic Liver Disease Compared With Other Chronic Diseases, 2004-2013. <i>Gastroenterology</i> , 2018, 155, 719-729.e4.	0.6	81
89	Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1207-1217.e4.	2.4	71
90	The Validity of HCC Diagnosis Codes in Chronic Hepatitis B Patients in the Veterans Health Administration. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1180-1185.	1.1	8

#	ARTICLE	IF	CITATIONS
91	NAFLD-Related HCC: How Should the Shift in Epidemiology Change Our Prevention and Surveillance Strategies?. <i>Current Hepatology Reports</i> , 2017, 16, 26-32.	0.4	0
92	Hepatitis C and Risk of Nonhepatic Malignancies. <i>Clinics in Liver Disease</i> , 2017, 21, 543-554.	1.0	15
93	The Top Five Reasons You Should Publish in <i>Clinical Gastroenterology and Hepatology</i> . <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 164-165.	2.4	2
94	Reply to: "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients". <i>Journal of Hepatology</i> , 2017, 67, 884-885.	1.8	1
95	Reply to: "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection". <i>Journal of Hepatology</i> , 2017, 67, 886-887.	1.8	1
96	Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2017, 153, 996-1005.e1.	0.6	680
97	Global epidemiology and burden of HCV infection and HCV-related disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 122-132.	8.2	317
98	Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. <i>Digestive Diseases and Sciences</i> , 2017, 62, 526-533.	1.1	27
99	Anniversary Tribute From the Editors of <i>Clinical Gastroenterology and Hepatology</i> . <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1823-1827.	2.4	0
100	Accurate Identification of Fatty Liver Disease in Data Warehouse Utilizing Natural Language Processing. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2713-2718.	1.1	28
101	Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 273-281.e1.	2.4	106
102	Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017, 66, 355-362.	1.8	104
103	Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 310-312.	2.4	12
104	Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. <i>Gastroenterology</i> , 2017, 152, 812-820.e5.	0.6	339
105	Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. <i>Hepatology</i> , 2017, 65, 777-788.	3.6	83
106	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 487-488.	2.4	0
107	Quality of Care in the Cirrhotic Patient. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e166.	1.3	18
108	Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2016, 63, 291-299.	2.9	60

#	ARTICLE	IF	CITATIONS
109	Prediction Models for Gastrointestinal and Liver Diseases: Too Many Developed, Too Few Validated. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1678-1680.	2.4	23
110	Collaborative Care for Depression in Chronic Hepatitis C Clinics. <i>Psychiatric Services</i> , 2016, 67, 1076-1082.	1.1	7
111	Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1714-1720.	1.1	72
112	Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 191-202.e4.	2.4	126
113	Trends in the Burden of Nonalcoholic Fatty Liver Disease in United States Cohort of Veterans. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 301-308.e2.	2.4	136
114	Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 124-131.e1.	2.4	471
115	Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2030-2037.	1.1	3
116	Use of Hyatt's Law, R Criteria, and nR Criteria to Predict Acute Liver Failure or Transplantation in Patients With Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2015, 148, 452.	0.6	3
117	Temporal Trends of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma in the Veteran Affairs Population. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 594-601.e1.	2.4	215
118	Nonalcoholic Fatty Liver Disease is Underrecognized in the Primary Care Setting. <i>American Journal of Gastroenterology</i> , 2015, 110, 10-14.	0.2	110
119	Pay for Performance in Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2042-2047.	2.4	8
120	Response to Li et al.. <i>American Journal of Gastroenterology</i> , 2015, 110, 774.	0.2	0
121	Why We Should Be Willing to Pay for Hepatitis C Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1711-1713.	2.4	10
122	Decreasing Mortality in Patients Hospitalized With Cirrhosis. <i>Gastroenterology</i> , 2015, 148, 897-900.	0.6	12
123	The Art and Science of Managing Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2029-2030.	2.4	1
124	Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. <i>Hepatology</i> , 2014, 60, 1871-1878.	3.6	67
125	New Diagnosis of Chronic Pancreatitis: Risk of Missing an Underlying Pancreatic Cancer. <i>American Journal of Gastroenterology</i> , 2014, 109, 1824-1830.	0.2	52
126	Improving Quality of Health Care for Patients With Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 1204-1207.	0.6	34

#	ARTICLE	IF	CITATIONS
127	The End of Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 533-536.	2.4	26
128	Primary Prophylaxis of Variceal Bleeding. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 783-794.	1.0	4
129	Racial Differences in the Progression to Cirrhosis and Hepatocellular Carcinoma in HCV-Infected Veterans. <i>American Journal of Gastroenterology</i> , 2014, 109, 1427-1435.	0.2	84
130	The Quality of Care Provided to Patients With Varices in the Department of Veterans Affairs. <i>American Journal of Gastroenterology</i> , 2014, 109, 934-940.	0.2	42
131	Hepatitis C Virus Treatment: The Unyielding Chasm Between Efficacy and Effectiveness. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1381-1383.	2.4	16
132	Increased Risk of Pancreatic Adenocarcinoma After Acute Pancreatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1143-1150.e1.	2.4	85
133	A New Laboratory-Based Algorithm to Predict Development of Hepatocellular Carcinoma in Patients With Hepatitis C and Cirrhosis. <i>Gastroenterology</i> , 2014, 146, 1249-1255.e1.	0.6	156
134	Many Patients With Interleukin 28B Genotypes Associated With Response to Therapy Are Ineligible for Treatment Because of Comorbidities. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 327-333.e1.	2.4	11
135	Improving quality of care in patients with cirrhosis. <i>Clinical Liver Disease</i> , 2013, 2, 123-124.	1.0	5
136	Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1342-1359.e2.	2.4	634
137	The Quality of Care Provided to Patients With Cirrhosis and Ascites in the Department of Veterans Affairs. <i>Gastroenterology</i> , 2012, 143, 70-77.	0.6	133
138	An Explicit Quality Indicator Set for Measurement of Quality of Care in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 709-717.	2.4	109